Summary Alpha L-Iduronidase (IDUA or EC 188.8.131.52) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I).
Alpha L-Iduronidase (IDUA or EC 184.108.40.206) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 8 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).
The latest report Alpha L-Iduronidase - Pipeline Review, H2 2020, outlays comprehensive information on the Alpha L-Iduronidase (IDUA or EC 220.127.116.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha L-Iduronidase (IDUA or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 22.214.171.124) - The report reviews Alpha L-Iduronidase (IDUA or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects - The report assesses Alpha L-Iduronidase (IDUA or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 220.127.116.11) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 18.104.22.168) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 22.214.171.124) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Hepatocyte Growth Factor - Pipeline Review, H2 2020 Summary According to the recently published report ’Hepatocyte Growth Factor - Pipeline Review, H2 2020’; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. Hepatocyte Growth...
Angina (Angina Pectoris) - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Angina - Pipeline Review, H2 2020, provides an overview of the Angina (Cardiovascular) pipeline landscape. Angina pectoris is a term that describes chest pain caused...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.